Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate (DCR) of 83%. The interim analysis included data from 29 evaluable fibroblast growth factor receptor 2 (FGFR2; KGFR; CD332) gene fusion-expressing patients.

Derazantinib is an orally administered small molecule inhibitor of FGFR. Basilea has exclusive rights to derazantinib from ArQule Inc. (NASDAQ:ARQL) outside of greater China (see "Basilea Gains Rights to ArQule's Derazantinib")...